The company has now received the renewed GMP (Good Manufacturing Practices) certificate thereby confirming the successful closure of the inspection
The GMP certificate is valid for three years until April 2024.
The company has received a certificate of Good Manufacturing Practice compliance from the Medicines & Healthcare products Regulatory Agency (MHRA) UK
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
Upgrades 2025 full-year CDMO sales and margin outlook
This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.
The company is addressing these observations comprehensively
This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms
Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility
Subscribe To Our Newsletter & Stay Updated
